4D Molecular Therapeutics (FDMT) Operating Margin Growth (3y) (2023 - 2026)

4D Molecular Therapeutics (FDMT) Operating Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 4D Molecular Therapeutics 706.51 Mn 315.62 Mn - 768,654.00

Historic Data

Download Data
DateValue
Mar 31, 2026 768,654.00
Dec 31, 2025 232,042.00
Sep 30, 2025 -6.27 Mn
Jun 30, 2025 -37.88 Mn
Mar 31, 2025 -38.08 Mn
Dec 31, 2024 -558.48 Mn
Sep 30, 2024 -170.27 Mn
Jun 30, 2024 -84.91 Mn
Mar 31, 2024 -13.54 Mn
Dec 31, 2023 19.31 Mn
Sep 30, 2023 3,616.00
Jun 30, 2023 -1.30 Mn
Mar 31, 2023 -972,710.00